Tango Therapeutics, Inc. (TNGX) stock
Close on Nov 11, 2026Market cap $4.34BP/E –Yield –
Tango Therapeutics, Inc. saw revenue fall 100.0% to $0 over the twelve months to Sep 30, 2026. Free cash flow was -$150.36M. At the latest close the market valued the company at $4.34B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.34B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.43
- Dividend yield
- –
- Free cash flow yield
- -3.47%
Fundamentals
- Revenue
- $0
- Net income
- -$208.00M
- EPS, diluted
- -$1.37
- Free cash flow
- -$150.36M
- Book value per share
- $5.64
- Diluted shares
- 174M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $24.30
- Open
- $24.68
- Day's range
- $23.86 – $26.41
- Volume
- 3,867,673
- Average volume (20 days)
- 4,212,760
- Index membership
- Russell 2000 (since Jun 2022), Russell 3000 (since Aug 2022)
- Beta (5 years)
- 1.17
- 52-week range
- $7.49 – $34.39
- RSI (14 days)
- 58.4
- Volatility (1 year)
- 101.3%
- Relative volume
- 1.25×
- WACC
- 10.8%
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TNGX | S&P 500 | Difference | TNGX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.1% | -2.4% | +10.5 pts | ||
| 3 months | -2.3% | -1.2% | −1.2 pts | ||
| Year to date | +190.4% | +12.3% | +178.1 pts | ||
| 1 year | +207.0% | +12.4% | +194.6 pts | ||
| 3 years | +207.8% | +78.8% | +129.0 pts | +45.5% | +21.4% |
| 5 years | +98.4% | +75.2% | +23.2 pts | +14.7% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tango Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% ObjectiveUpdate
About Tango Therapeutics
Pharmaceutical Preparations
Tango Therapeutics, Inc. is a precision oncology company focused on the development of novel therapies for patients diagnosed with genetically defined or biomarker-driven cancers. Utilizing synthetic lethal targeting designed to spare normal cells, the company discovers and advances oncology treatments targeting pathways such as MTAP-deleted cancers. Its clinical and research programs include therapeutic candidates such as vopimetostat (TNG462), TNG456, and other targeted molecules, which it develops as single agents or in combination therapies alongside strategic collaborators.
Company profile, executives and historyTango Therapeutics stock: common questions
What is Tango Therapeutics's stock price?
TNGX closed at $25.73 on Nov 11, 2026, up 5.88% on the day. Over the past 52 weeks it traded between $7.49 and $34.39.
What is Tango Therapeutics's market cap?
Tango Therapeutics was worth $4.34B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TNGX's P/E ratio?
Tango Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.37), so it has no meaningful P/E ratio.
How much revenue does Tango Therapeutics make?
Tango Therapeutics reported revenue of $0 for the twelve months to Sep 30, 2026, down 100.0% from a year earlier.
Does Tango Therapeutics pay a dividend?
No. Tango Therapeutics has not paid a cash dividend over the last twelve months.
When does Tango Therapeutics report earnings next?
Tango Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TNGX stock performed over the past year?
Including dividends, TNGX returned +207.0% over the past year, against +12.4% for the S&P 500.
How many TNGX shares are sold short?
48M shares were sold short at the latest FINRA report, 32.39% of the float, or 9.7 days of average trading volume.
Who are Tango Therapeutics's competitors?
Companies most similar to Tango Therapeutics by business, industry and size include XLO, PRLD, FHTX, KURA, NKTR.
See a number that looks wrong?